https://www.prognyx.com/blog/per-endpoints-elevar-s-lyrfigtu-wins-first-fda-nod-in-fgfr2-bile-duct-cancerPrognyxen2026-09-24Per Endpoints, Elevar's Lyrfigtu wins first FDA nod in FGFR2 bile duct cancer https://www.prognyx.com/blog/sotio-s-sot106-adc-lands-fda-orphan-drug-and-osteosarcoma-fast-trackPrognyxen2026-09-23SOTIO's SOT106 ADC lands FDA Orphan Drug and osteosarcoma Fast Track